3D Medicines Inc
01244
Company Profile
Business description
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
Contact
No. 3 and No. 5, Laiyang Road
Shandong Province, Shinan District
Qingdao
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
162
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,417.60 | 19.80 | -0.21% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,830.08 | 162.05 | 0.63% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,862.52 | 1,255.81 | 1.91% |
| NZX 50 Index | 13,844.17 | 20.04 | 0.14% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,228.60 | 21.00 | -0.23% |
| SSE Composite Index | 3,947.91 | 7.87 | 0.20% |